Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Minerva Neurosciences (NERV) Liabilities and Shareholders Equity (2016 - 2026)

Minerva Neurosciences filings provide 3 years of Liabilities and Shareholders Equity readings, the most recent being $77.1 million for Q4 2021.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 33.83% to $77.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $391.8 million, a 51.99% increase, with the full-year FY2021 number at $77.1 million, up 33.83% from a year prior.
  • Liabilities and Shareholders Equity hit $77.1 million in Q4 2021 for Minerva Neurosciences, down from $97.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $111.8 million in Q1 2021 to a low of $57.6 million in Q4 2020.
  • Median Liabilities and Shareholders Equity over the past 3 years was $77.1 million (2021), compared with a mean of $80.8 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 25.64% in 2020 and later soared 62.58% in 2021.
  • Minerva Neurosciences' Liabilities and Shareholders Equity stood at $77.5 million in 2019, then dropped by 25.64% to $57.6 million in 2020, then skyrocketed by 33.83% to $77.1 million in 2021.
  • The last three reported values for Liabilities and Shareholders Equity were $77.1 million (Q4 2021), $97.6 million (Q3 2021), and $105.3 million (Q2 2021) per Business Quant data.